ZYDUSLIFE1,118.50

Zydus Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYCIPLATORNTPHARMDIVISLABMAXHEALTHAPOLLOHOSPAUROPHARMAMcap ₹1.13L Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation764.1915.81,408.0
+ Finance Costs75.6160.1365.0
+ Interest Income-126.8-185.2-422.5
+ Dividend Income-1.3-1.0-1.2
+ Fair Value (Gains) / Losses0.00.0-29.2
+ Unrealised FX (Gain) / Loss0.0-137.9-1,753.3
+ Other Non-cash Items-148.3291.1144.8
+ Other — Cash Effects are Investing / Financing-54.3-99.5-2.3
+ Other Reconciling Items29.20.00.0
Changes in Working Capital
+ Inventories-2.0-444.9-412.4
+ Trade Receivables — Current-747.21,255.8-858.1
+ Other Current Assets-144.2110.9-461.8
+ Trade Payables — Current-44.898.6-795.1
+ Other Current Liabilities67.1511.1-96.3
+ Provisions — Current17.060.354.9
+ Provisions — Non-current20.716.7-54.0
Cash from Operating Activities
Profit Before Tax (per I/S)4,808.96,026.76,621.16,007.1
+ Total Adjustments (incl. Working Capital)-295.22,551.9-2,913.5
Cash from Operations (pre-tax)4,513.78,578.63,707.6
+ Income Taxes Paid1,285.81,801.91,591.0
Cash from Operating Activities3,227.96,776.72,116.6
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)906.61,712.63,394.0
+ Disp of Fixed Assets23.751.424.9
+ Acq of Other Long-term Assets357.80.00.0
+ Disp of Other Long-term Assets407.70.00.0
+ Purchase of Investments (Equity / Debt)106.742.5345.2
+ Sale of Investments (Equity / Debt)55.0216.0112.0
+ Acq of Interests in Joint Ventures0.0670.80.0
+ Disp of Interests in Joint Ventures0.018.50.0
+ Acq of Subsidiaries / Businesses (net)720.1369.05,879.3
+ Loans & Advances Made-0.975.60.0
+ Loans & Advances Repaid0.00.073.2
+ Dividends Received — Investing1.31.01.2
+ Interest Received — Investing127.4181.5427.2
+ Other Inflows / (Outflows) — Investing0.0-5,970.2683.9
Cash from Investing Activities-1,475.2-8,372.3-8,296.1
Cash from Financing Activities
+ Buyback / Redemption of Own Shares725.00.00.0
+ Proceeds from Borrowings0.02,402.08,260.2
+ Repayment of Borrowings392.90.0967.9
+ Payment of Lease Liabilities-1.4-4.225.5
+ Interest Paid72.989.5353.6
+ Dividends Paid621.0302.51,106.3
+ Other Inflows / (Outflows) — Financing6.016.6190.2
Cash from Financing Activities-1,804.42,030.85,997.1
Net Changes in Cash (pre-FX)-51.7435.2-182.4
+ Effect of FX Rate Changes on Cash-23.1-21.4210.8
Net Changes in Cash-74.8413.828.4
Closing Cash413.0826.8
Reference Items
EBITDA5,384.37,058.58,475.18,316.0
EBITDA Margin %27.5430.3731.2229.09
Free Cash Flow (CFO − Capex)2,321.35,064.1-1,277.4-1,277.4
Free Cash Flow to Equity7,375.56,969.0
Free Cash Flow per Basic Share23.0750.34-12.70-12.70
Cash Flow to Net Income0.811.450.41
Cash Paid for Taxes1,285.81,801.91,591.0
Cash Paid for Interest72.989.5353.6
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.